Impact BioMedical 10-Q: Going Concern Warning With Just $21,000 Cash on Hand
IBO sits 78% above its 52-week low of $2.43 on light trading volume (0.3× avg).
Summary
Impact BioMedical reported a $3,629,000 nine-month net loss with only $21,000 of cash and repeated its going-concern warning. The pending Zoar merger, expected to close in Q4 2026, is the main path to survival.
Key Events · Earnings and Guidance · IBO
-
Going Concern Doubt Reiterated
Management states operating losses and negative operating cash flows over the past two years raise substantial doubt about the ability to continue as a going concern within one year of issuance.
-
Cash of Only $21,000
Cash was $21,000 at September 30, 2026 versus total current liabilities of $2,373,000, including $1,623,000 due to related party DSS.
-
Nine-Month Loss Narrows to $3.6M
Net loss was $3,629,000 versus $17,105,000 a year earlier, but the prior year included a $13,210,000 non-cash fair-value charge on the DSS note; revenue was just $31,000.
-
Zoar Merger Pending for Q4 2026
The SEC declared Zoar's Form F-4 effective October 23, 2026; closing remains subject to stockholder and regulatory approvals and NYSE American listing approval.
Analysis · IBO · Life Sciences
With $21,000 of cash against $2,373,000 of current liabilities, management states substantial doubt about the company's ability to continue as a going concern within one year. Revenue is negligible at $31,000 for nine months, so operations cannot fund the business; survival depends on the pending Zoar merger closing in Q4 2026 or new capital. The net loss narrowed to $3,629,000 from $17,105,000, but that improvement is mostly the absence of last year's $13,210,000 non-cash fair-value charge on the DSS note, not better operations. Disclosure controls were also still not effective.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IBO was trading at $4.33 on NYSE in the Life Sciences sector, with a market capitalization of approximately $37.4M. The 52-week trading range was $2.43 to $10.47. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.